Related conditions

IgG4-related disease with bone marrow involvement mimicking multiple myeloma. Tang SH et al. Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14651. [Epub ahead of print]. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Rodríguez-Lobato LG et al. Biol Blood Marrow Transplant. 2017 Apr 18. pii: S1083-8791(17)30400-7. doi: 10.1016/j.bbmt.2017.04.012. [Epub ahead of print]. Crystalglobulinemia manifesting as chronic arthralgia…

Journal, Library

Emerging treatments

Phase I trial of systemic administration of edmonston strain of measles virus, genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Dispenzieri A et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.120. [Epub ahead of print]. Moving beyond maximum tolerated dose for targeted oncology drugs: Use of clinical utility index to optimize venetoclax…

Journal, Library

Biology and genetics

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Mishima Y et al. Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Dupéré-Richer D et al. Curr Opin Hematol. 2017 Apr 22. doi: 10.1097/MOH.0000000000000358. [Epub ahead of print]. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple…

Journal, Library, Management of Myeloma

General

Daratumumab for the treatment of multiple myeloma. Touzeau C et al. Expert Opin Biol Ther. 2017 Apr 24. doi: 10.1080/14712598.2017.1322578. [Epub ahead of print]. New developments in the treatment of multiple myeloma – clinical utility of daratumumab. McEllistrim C et al. Biologics. 2017 Apr 11;11:31-43. doi: 10.2147/BTT.S97633. eCollection 2017. Immunologic approaches for the treatment of multiple myeloma. Rasche L et al. Cancer Treat Rev. 2017 Apr 6;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. [Epub ahead of print]. Which…

Journal, Library

Supportive treatments

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Richardson PG et al. Br J Haematol. 2017 Apr 26. doi: 10.1111/bjh.14727. [Epub ahead of print]. Trends in vertebral augmentation for spinal fractures in myeloma patients: a 2002-2012 population-based study using a large national cancer registry. Chokshi FH et al. J Neurointerv Surg. 2017 Apr…

Journal, Library, Myeloma Prognosis & Outcomes

Complications of myeloma and its treatments

Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Lee SE et al. Anticancer Drugs. 2017 Apr 20. doi: 10.1097/CAD.0000000000000506. [Epub ahead of print]. Paraneoplastic acute disseminated encephalomyelitis associated with multiple myeloma. Law LY et al. Mult Scler Relat Disord. 2017 Apr;13:21-24. doi: 10.1016/j.msard.2017.01.013. Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD):…

Journal, Library, Management of complications & side effects

Current treatments

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Bahlis NJ et al. Leukemia. 2017 Apr 4. doi: 10.1038/leu.2017.111. [Epub ahead of print]. Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma. Knop S et al. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.124. [Epub ahead of print]. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation…

Journal, Library

IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

Clinical guidelines & position statements, Imaging & Analysis, IMWG, Library